Antares Pharma, Inc. (ATRS)

[H2R]

SoS: Antares: Things Are Looking Up (ATRS, Buy, $2.22)

POSTED by LARRY SMITH on MAR 5, 2018 • (2)

Overview of Report

I listened to the presentation by CEO Bob Apple at the Raymond James conference on March 5th and go over his key remarks in this report I have been frustrated by the CRL for Xyosted and delays in approval for AB rated versions of EpiPen and Byetta which have had a sharply negative impact on the stock. However, the recent approval of Makena SC was a shot in the arm (for both Antares and patients). I think that within two weeks we are likely to hear a clear path forward to approval for Xyosted and I think that approval of the AB rated version of EpiPen is highly likely in the near and approval of the AB rated version of Byetta could also come in 2018. The year 2018 could be a breakout year for Antares.

https://smithonstocks.com/antares-things-are-looking-up-atrs-buy-2-22/